Abilifay

Indications Abilifay

Abilife is intended for people suffering from schizophrenia. It is used both during the exacerbation period and for maintenance treatment. Abilifay is also prescribed for acute manic episodes of type 1 in manic-depressive psychosis, and also as a supporting treatment for bipolar affective disorders. Abiliphy can be used as an auxiliary treatment for depressive disorders. According to some experts, the drug can be used to treat alcoholism.

[1]

Release form

The form of release of the drug Abilifay: tablets of round or rectangular shape of different dosage and color:

• with mark A - 007 and 5, color - blue (5 mg);
• with mark A - 008 and 10, color - pink (10 mg);
• with mark A - 009 and 15, color - yellow (15 mg);
• with mark A - 010 and 20, color - white or pale yellow (20 mg);
• with a mark A - 011 and 30, color - pink (30 mg).

[2]

Pharmacodynamics

Abiliphay is an antagonist of dopamine receptors of the D2 subtype in the mesolimbic system, while partially being an agonist of the same receptors in the mesocortical system. The drug is a potent antagonist of serotonin 5 - HT 2 A receptor subtypes and a 5 - HT1A receptor agonist. Abiliphy has the lowest affinity of all atypical antipsychotics to adrenoreceptors (α 1), histamine (H 1) receptors and to M-cholinoreceptors (m 1). Such pharmacodynamics of abiliphy explains the high therapeutic effect of the drug in the treatment of schizophrenia and bipolar disorders, as well as the low incidence and severity of side effects. The drug is able to lower the blood levels of prolactin, glucose and lipids. An essential positive property of the drug is its ability to reduce the Q T-interval in ECG.

[3], [4], [5], [6]

Pharmacokinetics

The average half-life of the active substance is about seventy-five hours. Isostatic concentration is noted after fourteen days. The pharmacokinetics of abiliphas in the isostatic state are proportional to the dosage. The fluctuations in the distribution of the active substance per day and its metabolite are not noted. The drug is rapidly absorbed. Limit concentration is noted after three to five hours. The total ability of the drug to digest is eighty seven percent, regardless of the use of food. Less than one percent of unchanged aripiprazole is determined in urine and about eighteen percent of the substance used is unchanged in the form of calves. The total purification rate is 0.7 ml / min / kg.

[7], [8], [9], [10], [11], [12]

Dosing and administration

The method of administration and dose of the drug Abilifai in schizophrenia is initially ten to fifteen milligrams once a day, regardless of the intake of food. The maintenance dosage is fifteen milligrams per day. According to clinical data, the effective daily dosage of the drug is from ten to thirty milligrams. In the case of manic episodes, the recommended dose at the beginning of treatment is fifteen milligrams per day, regardless of eating. If necessary, the dosage adjustment interval should be at least twenty-four hours. During clinical trials, the drug was effective at a dosage of fifteen to thirty milligrams per day for a period of three to twelve weeks. Clinical data on the safety of taking the drug at a dosage of more than thirty milligrams a day are absent. To identify the need to appoint supportive treatment, you need to conduct periodic examination of the patient.

When using preparations containing lithium or valproic acid, the recommended dosage of abiliph at the beginning of treatment is fifteen milligrams once a day, regardless of eating. Dosage can be changed to thirty milligrams per day in accordance with the disease pattern.

With depressive disorders when used together with antidepressant medications, the recommended dosage of the drug Abiliphas is initially five milligrams per day. In accordance with the indications, the daily dosage of the drug Abiliph can be increased by five milligrams a week, but not more than fifteen milligrams per day. Patients with renal or hepatic impairment, as well as patients aged more than sixty-five years, do not need to change the dosage.

[19], [20]

Use Abilifay during pregnancy

The use of abiliph during pregnancy is allowed in situations where the expected efficacy of treatment exceeds the potential threat to the fetus. Detailed studies regarding the safety of treatment with abiliphas during pregnancy have not been conducted.

Contraindications

Contraindications to the use of abiliphas include hypersensitivity to aripiprazole or to any constituents of the drug, as well as age to eighteen years and the period of breastfeeding.

[13], [14], [15], [16], [17]

Side effects Abilifay

Side effects of abilifa can include negative reactions of the cardiovascular and digestive system, the musculoskeletal system, the nervous and respiratory systems, as well as the skin, sensory organs, metabolism, and the genitourinary tract. It is rare to have allergic manifestations - anaphylaxis, angioedema, itching, urticaria.

[18]

Overdose

An overdose of the drug abilifay can cause symptoms such as nausea and vomiting, asthenic syndrome, diarrhea, a feeling of drowsiness, increased heart rate, extrapyramidal disorders, fainting. Symptomatic therapy is used to treat symptoms.

[21], [22], [23], [24], [25],

Interactions with other drugs

On the pharmacokinetics of the drug abilifay does not have a significant effect of H2 - a blocker of histamine receptors, famotidine, which inhibits the release of hydrochloric acid. Quinidine and ketoconazole may lower the aripiprazole excretion rate by ingestion by fifty-two and thirty-eight percent, respectively (a reduction in the dosage of the drug abilifai is recommended). Carbamazepine reduces sixty-eight and seventy-three percent C _max and AUC of the active substance of the drug, and sixty-nine and seventy-one percent C max and AUC of dehydro-aripiprazole.

[26], [27], [28], [29], [30], [31]

Storage conditions

Conditions for storing abilifa: the drug should be stored out of reach of children in a dry place at temperatures from fifteen to thirty degrees.

[32], [33], [34], [35],

Shelf life

The shelf life of the drug abilifay is three years.

[36], [37], [38]